검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | NK cell therapy |
Overview Company | Royan Institute |
Overview Modality | CGT |
Overview Target | Glioma Glioblastoma Multiforme |
Overview Indication | Glioblastoma Multiform; Recurrent Glioblastoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen |
MoA Biomarker | biomarker of disease biology |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.. Patients with unresectable locally advanced or metastatic solid tumors have limited therapeutic options. Antibody-guided allogeneic natural killer (NK) cell therapy represents a novel immunotherapeutic strategy to enhance tumor targeting and cytotoxicity by coupling NK cells… |
Toxicology CRS | Reported |
Clinical OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT00787761 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | NK cell therapy |
Overview Company | Royan Institute |
Overview Modality | CGT |
Overview Target | Glioma Glioblastoma Multiforme |
Overview Indication | Glioblastoma Multiform; Recurrent Glioblastoma |
Overview Phase | PHASE_1 |
Overview Status | ACTIVE |
MoA Mechanism | targeting and cytotoxicity by coupling NK cells with tumor-specific antibodies targeting antigen |
MoA Biomarker | biomarker of disease biology |
PK/PD Species | Mouse |
PK/PD Animal (cat.) | Mouse, In vitro |
PK/PD Experiment | PD |
Toxicology Species | Mouse |
Toxicology Animal (cat.) | Mouse, In vitro |
Toxicology Major finding | Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.. Patients with unresectable locally advanced or metastatic solid tumors have limited therapeutic options. Antibody-guided allogeneic natural killer (NK) cell therapy represents a novel immunotherapeutic strategy to enhance tumor targeting and cytotoxicity by coupling NK cells… |
Toxicology CRS | Reported |
Clinical OS | 16 |
Clinical Result source | ClinicalTrials.gov NCT00787761 |
Clinical Data Tier / Score | A · 31 |
Clinical Program phase | PHASE_1 |
Clinical Clinical sync | 2026년 7월 13일 (1일 전) |
추천 비교
추천 비교